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tinuous rather than distinctive entities or the cost-benefit ra-
tio reaches an unfordable level. Answers to these questions de-
pend greatly on the values of the population concerned and
resources available.2-4
Our recent study5 showed that the changes in the cutoffs
for diagnosing hypertension, hypercholesterolemia, and dia-
betes mellitus around the year 2000 resulted in doubling the
prevalence of all the 3 conditions in China.5 If the new patients
were all treated with drugs, the annual drug costs alone would
consume 56% of the government’s total health expenditure in
2010.5 Regardless of the benefit of treating these conditions,
which is bound to be small, it is unlikely affordable for China.
Indeed, most uninsured patients with hypertension in the coun-
try were unwilling to take drugs as guidelines recommended.
This implies importantly that populations with different
values and resources available for health care should con-
sider different cutoff values; for example, the World Health
Organization recommended 3 different cutoff values for car-
diovascular risk above which drug interventions are recom-
mended.3,4 Opposed to how the disease was originally defined,
this approach adds a subjective, value-laden component that
entails further discussions.
Much of the above discussions equally apply to new defini-
tions of diseases. Finally, do risk, benefit, and harm make a com-
plete list of necessary criteria? If not, what other factors should
be considered? Methods and procedures for modifying disease
definitions should also be elaborated. Changes should be based
on current best evidence, and strong evidence must be provided.
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In Reply We thank Dr Yang and colleagues for raising impor-
tant points regarding our Special Communication1 on modi-
fying disease definitions, many of which we alluded to in our
article but that we agree need further discussion.
We agree with Dr Yang and colleagues that when modify-
ing a disease definition, it is essential to consider whether the
additional patients classified with the expanded definition war-
rant clinical intervention, as well as whether this net benefit
should be paid for. Such decisions should include consider-
ation of the regional variations in the values of the popula-
tion concerned and their available resources. In our check-
list, we recommended that the definition should reflect the
values and preferences of patients and the wider community
and include the impact on resource usage.1
Dr Yang and colleagues have highlighted an important con-
sequence of this recommendation: that different disease defi-
nitions for clinical care may then be appropriate in different
countries. The World Health Organization has recognized this
problem with the recommendation that different countries use
different levels of risk for the primary prevention of cardio-
vascular disease.2
Our article1 outlines a checklist of issues that we recom-
mend should be considered and reviewed prior to making a
recommendation to modify a disease definition. The check-
list is not a set of criteria. We hope that the checklist will im-
prove the transparency of the methods and processes used
when disease definitions are being modified. We agree that the
current checklist1 is just the beginning of work in this impor-
tant area of research and that the checklist requires testing and
extension in a variety of conditions and settings.
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Concerns About Conclusions of Self-monitoring
of Blood Glucose
To the Editor In a recent issue of JAMA Internal Medicine, an Origi-
nal Investigation by Young et al1 reports the results of a random-
ized clinical study wherein use of daily self-monitoring of blood
glucose failed to improve glycated hemoglobin (HbA1c) levels
compared with the study’s control participants. Young et al1 con-
clude that glucose monitoring in patients with non–insulin-
treated type 2 diabetes should not be routine, and Figure 1 shows
a reduction of HbA1c by 0.35% in patients using self-monitoring
of blood glucose after 6 months. Glycated hemoglobin levels
gradually returned to baseline levels by 1 year, but 33% of study
participants had stopped monitoring after 6 months while 40%
to 60% stopped monitoring after 1 year.1 If half the participants
did not adhere to the intervention, a sustained response should
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not have been expected, especially with the well-known pro-
gression of glucose intolerance in type 2 diabetes.
Concerning limitations of experimental design and imple-
mentation of the study,1 there was no contact between the
study group and patients between the study initiation and ter-
mination. Young et al1 presented no evidence that either the
patients or the primary care physicians were trained and/or
competent in the interpretation and usage of glucose data. It
is unknown how often physicians adjusted therapy or whether
participants adjusted diet, activity, or medication usage. The
average baseline HbA1c level (7.5%) was not markedly el-
evated, and it is unspecified whether individualized goals for
improvement were set for HbA1c or fasting plasma glucose.
We are concerned about a long-term controversy because
there is a vast literature on benefits of self-monitoring of blood
glucose in type 2 diabetes.2 There is a consensus that self-
monitoring of blood glucose, when used properly, can im-
prove HbA1c in patients with type 2 diabetes not receiving
insulin2 alongside glucose data being used by patients and phy-
sicians to adjust therapy and lifestyle. Structured testing (ie,
multiple glucose values per day [premeal, postmeal, bed-
time, overnight] to define the ambulatory glucose profile) can
provide superior, actionable information3 that promotes in-
teraction with health care clinicians, enables adjustment of
therapy, and significantly improves HbA1c.4
The current generation of mobile applications automati-
cally collect data regarding glucose, diet (ie, carbohydrates and
calories), medications, and physical activity, and provide real-
time reminders for monitoring glucose and taking medica-
tions,5 interpretation of results, insights, motivational mes-
sages, alerts and warnings, online access to certified diabetes
educator coaches, educational materials, news items, reci-
pes, and support from the online diabetes community. Sev-
eral of these applications have been demonstrated to provide
major reductions in HbA1c and improved self-care in well-
motivated patients.5
Numerous studies have shown that self-monitoring of
blood glucose, properly implemented, can improve HbA1c in
patients with non–insulin-treated type 2 diabetes.2-5
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In Reply We thank Pimazoni-Netto et al for their letter and in-
clude our response to their concerns. In considering our pub-
lished results,1 it is of tantamount importance that readers un-
derstand the tenets of comparative effectiveness research
(CER). Comparative effectiveness research studies are prag-
matic in nature, and they are designed to: (1) inform health care
decisions and/or policy; (2) evaluate 2 or more interventions
that have the potential to represent best practice; and (3) be
executed in real-world, clinical settings.2 The MONITOR trial1
was designed as a comparative effectiveness trial. For those
steeped in the traditions of efficacy trials, fully embracing the
tenets of CER can be challenging.
We selected high-quality, primary care practices in an aca-
demic health care organization. The primary care providers were
experienced, high-performing clinicians. This is evidenced in
part by the mean glycated hemoglobin (HbA1c) of 7.5% across
the practices at baseline. Throughout the trial1 we delivered ad-
ditional trainings to the practices both on the implementation
of the study and general management of diabetes. In keeping
with the spirit of CER, we intentionally designed the study such
that our interactions with the patients were minimized. It is not
unusual for patients not enrolled in a clinical trial to tire of self-
monitoring of blood glucose (SMBG). This is regularly seen in
routine clinical practice. Thus, we feel our results reflect pri-
mary care effectiveness, arguably in a better-than-average prac-
tice setting. Frankly, we hoped and expected to demonstrate
benefits, particularly of the enhanced use of SMBG-tailored mes-
saging. Nevertheless, our study1 demonstrated that SMBG had
no effect on participant HbA1c levels over the course of a year.
We remain hopeful that new technology and better implemen-
tation strategies can be developed and validated in a future CER
study to improve outcomes that are important to patients.
The bottom line remains that previous trials of SMBG in pa-
tients with non–insulin-treated type 2 diabetes have not uni-
formly demonstrated a benefit. Our pragmatic trial adds to the
base of literature. Glucose monitoring is a multi-billion-dollar
business. If we can relieve society of its cost, patients of their
burden, and health care providers of prescribing and review-
ing the results, we can encourage each to embrace more fruit-
ful avenues of therapy, including lifestyle intervention and drug
adherence. Based upon the results of our trial,1 we suggest that
comprehensive lifestyle intervention and modern drug thera-
pies in the preinsulin phase of diabetes management without
routine SMBG can be effective in controlling HbA1c and other
parameters of glycemic control at least in patients who are well
informed and on the fence with regards to the value of SMBG.
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Selection Does Not Equate Consumption
To the Editor We applaud Turnwald et al1 for their experimen-
tal design to test inexpensive interventions to increase healthy
food consumption within the Stanford University dining hall.
In a Research Letter published in a recent issue of JAMA Internal
Medicine, Turnwald et al1 reported that indulgent descriptors
of healthy vegetables dramatically increased “consumption”
compared with alternatively labeling the same food. The as-
sumption that measuring the quantity of a vegetable selected
equates to consumption is flawed and may misrepresent the
results and overstate the conclusions. The authors cited a re-
view by Wansink and Johnson2 that found that on average 92%
of foods selected are consumed.
However, many of the studies reviewed were in a food labo-
ratory and were single experiments without the context of a
free-living population on a college campus with repeated ex-
posures to the same food. Additionally, consumption was much
lower in studies of individual food items. There is also not ad-
equate literature specifically on vegetable consumption, which
traditionally is consumed less than other “healthy” foods, such
as fruits, whole grains, lean meats, and dairy2; in our studies,3-5
we observed substantially greater consumption of these
healthier items compared with vegetables.
For example, in our plate waste study in a cafeteria setting
measuring thousands of participants over time, we found that
while similar marketing techniques can result in increased se-
lection of vegetables, students consumed on average as little as
18% of these items.3 We found that upgrading the taste through
a chef intervention had the best long-term impact on real con-
sumption. While our research was conducted among a younger
population, it is still relevant in highlighting the need to mea-
sure actual consumption among study participants.
While we believe that research that furthers our under-
standing of effective promotion strategies for healthier foods
is critically important, it is equally important for researchers
to move beyond measuring just selection and to focus on taste
and actual consumption.
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In Reply We agree with Dr Cohen and colleagues about the im-
portance of measuring taste and consumption. We also agree
that work should be done to upgrade the preparation of healthy
foods. The ultimate taste and experience of any food is a syn-
ergy of quality ingredients, their preparation, and one’s mind-
set about those foods.1,2 Thus, improving consumption is best
achieved by changing both our negative mindsets about healthy
foods and the preparation of the foods themselves.
In our study,1 we counted every diner who chose veg-
etables and weighed each serving dish as it was placed on and
removed from the serving line on each of 46 days. While mea-
suring plate waste would help approximate consumption, col-
lecting and measuring waste is difficult and prone to error. The
few studies that have taken to the arduous task of weighing
waste understandably do so only on a handful of days,3,4 there-
fore introducing error with respect to representativeness and
generalization across a variety of vegetables. Given these
tradeoffs, we elected to concentrate on robustly measuring
selection on all 46 days of our intervention.
Several reasons lead us to believe that consumption was
indeed affected. First, if the indulgently labeled vegetables led
people to select them but ultimately dislike them, any differ-
ences in selection observed early in the study would disap-
pear or reverse over time. This is not what we observed. Sec-
ond, contrary to their statement, the review5 cited by Cohen
does contain field studies and reports no difference in con-
sumption rates between field and laboratory studies. The same
review reports that self-served food consumption is greater in
adults compared with children (92% vs 59%),5 which may ex-
plain the low consumption rates observed by Cohen and col-
leagues in their own studies of children.3,4 Third, Cohen and
colleagues correctly state that vegetables are consumed at lower
rates than other healthy foods; however, low base rates of con-
sumption bear no relevance on how consumption rates may
change in response to intervention. In fact, Cohen and col-
leagues themselves observed that vegetable consumption rates
increased as much as or more than other healthy foods after
intervention.3,4 Finally, we did actually measure taste among
more than 200 diners on 2 days during the intervention and
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